Skip to main content
PMC home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 1999 Apr-Jun;41(2):96–99.

REEMERGENCE OF POSITIVE SYMPTOMS OF SCHIZOPHRENIA DURING THE COURSE OF TREATMENT WITH RISPERIDONE

Priya Bajaj *, Nikhil Nihalani †, Nilesh Shah *,*, Neena Desai §, Veena Shinde , Nivedita Raut #
PMCID: PMC2962850  PMID: 21455369

Abstract

Thirty patients suffering from schizophrenia (diagnosed as per DSM-IV criteria), for more than 2 years and having predominant negative symptoms were started on risperidone (2-10 mg/day) and were followed up over a period of 16 weeks. The improvement was assessed using PANSS (Positive and Negative Syndrome Scale).

During this 16 weeks follow up, it was interestingly noted that though there was a significant improvement in negative symptoms in all the patients, in 7 patients there was a reemergence of positive symptoms. Four patients had increase in rating on suspiciousness and hostility and two patients reported auditory hallucinations. One patient developed delusions and conceptual disorganization along with suspiciousness and hostility.

Keywords: Risperidone, positive symptoms, schizophrenia

Full Text

The Full Text of this article is available as a PDF (158.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bondolfi G., Dufour H., Patris M., May J. P., Billeter U., Eap C. B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998 Apr;155(4):499–504. doi: 10.1176/ajp.155.4.499. [DOI] [PubMed] [Google Scholar]
  2. Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995 Nov;10(4):207–213. doi: 10.1097/00004850-199511000-00001. [DOI] [PubMed] [Google Scholar]
  3. Cesková E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993 Jul;26(4):121–124. [PubMed] [Google Scholar]
  4. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
  5. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x. [DOI] [PubMed] [Google Scholar]
  6. Cung D. D., Stimmel G. L. Reemergence of positive symptoms after initial response to risperidone. Pharmacotherapy. 1997 Mar-Apr;17(2):383–386. [PubMed] [Google Scholar]
  7. Davis K. L., Kahn R. S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov;148(11):1474–1486. doi: 10.1176/ajp.148.11.1474. [DOI] [PubMed] [Google Scholar]
  8. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996 Apr;153(4):466–476. doi: 10.1176/ajp.153.4.466. [DOI] [PubMed] [Google Scholar]
  9. Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
  10. Kibel D. A., Laffont I., Liddle P. F. The composition of the negative syndrome of chronic schizophrenia. Br J Psychiatry. 1993 Jun;162:744–750. doi: 10.1192/bjp.162.6.744. [DOI] [PubMed] [Google Scholar]
  11. Love R. C. Novel versus conventional antipsychotic drugs. Pharmacotherapy. 1996 Jan-Feb;16(1 Pt 2):6–10. [PubMed] [Google Scholar]
  12. Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]
  13. McGlashan T. H., Fenton W. S. The positive-negative distinction in schizophrenia. Review of natural history validators. Arch Gen Psychiatry. 1992 Jan;49(1):63–72. doi: 10.1001/archpsyc.1992.01820010063008. [DOI] [PubMed] [Google Scholar]
  14. Peralta V., Cuesta M. J. Symptoms of the schizophrenic negative syndrome. Br J Psychiatry. 1996 Aug;169(2):209–212. doi: 10.1192/bjp.169.2.209. [DOI] [PubMed] [Google Scholar]
  15. Volonté M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182–190. doi: 10.1046/j.1471-4159.1997.69010182.x. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES